Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myeloproliferative Chronic Myelomonocytic Leukemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03746041
What this trial is testing

A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic SyndromesChronic Myelomonocytic Leukemia
University of Rochester 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05038592
What this trial is testing

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Who this might be right for
Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2+1 more
M.D. Anderson Cancer Center 64
Not applicableLooking for participantsNCT03280888
What this trial is testing

Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Chronic Myelomonocytic Leukemia
Centre Hospitalier Universitaire de Nice 50
Testing effectiveness (Phase 2)Study completedNCT01445080
What this trial is testing

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Who this might be right for
Blastic PhaseChildhood Acute Promyelocytic Leukemia With PML-RARAChildhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive+7 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Study completedNCT00049634
What this trial is testing

Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic Syndromes+1 more
Fred Hutchinson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT01824693
What this trial is testing

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Who this might be right for
Juvenile Myelomonocytic Leukemia
Children's Oncology Group 30
Testing effectiveness (Phase 2)Study completedNCT00003675
What this trial is testing

Topotecan in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic Syndromes
Alliance for Clinical Trials in Oncology 100
Early research (Phase 1)Study completedNCT04167917
What this trial is testing

NTX-301 in MDS/AML

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia
University of Alabama at Birmingham 22
Not applicableStudy completedNCT00014235
What this trial is testing

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia/Transient Myeloproliferative DisorderAcute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in Remission+74 more
Fred Hutchinson Cancer Center 160
Testing effectiveness (Phase 2)Ended earlyNCT00113321
What this trial is testing

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT04487106
What this trial is testing

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT00423514
What this trial is testing

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Who this might be right for
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
Memorial Sloan Kettering Cancer Center 38
Testing effectiveness (Phase 2)Study completedNCT00357084
What this trial is testing

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Who this might be right for
Cancer
Fred Hutchinson Cancer Center 53
Early research (Phase 1)Ended earlyNCT00589316
What this trial is testing

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+7 more
Fred Hutchinson Cancer Center
Large-scale testing (Phase 3)UnknownNCT00043134
What this trial is testing

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
European Organisation for Research and Treatment of Cancer - EORTC 220
Testing effectiveness (Phase 2)WithdrawnNCT06597734
What this trial is testing

Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Who this might be right for
Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02084563
What this trial is testing

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Who this might be right for
Acute Myeloid LeukemiaMyeloproliferative NeoplasmsMyelodysplastic Syndromes+1 more
Hospital Israelita Albert Einstein 455
Testing effectiveness (Phase 2)Study completedNCT02610777
What this trial is testing

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Millennium Pharmaceuticals, Inc. 120
Testing effectiveness (Phase 2)Study completedNCT01776723
What this trial is testing

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

Who this might be right for
Myelomonocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute 50
Not applicableStudy completedNCT00248547
What this trial is testing

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Who this might be right for
Cancer
OHSU Knight Cancer Institute 40
Next Page
26